Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Elias Zerhouni Talks Public Health Challenges, Culture Wars at WBBA Annual Meeting
|
Gregory T. Huang |
11/06/09 |
Seattle
|
|
Gloucester Pharma Wins FDA Approval of Drug for Rare Skin Cancer
|
Luke Timmerman |
11/05/09 |
Boston
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Ironwood, Forest Labs Drug for Chronic Constipation Passes Two Pivotal Trials
|
Luke Timmerman |
11/03/09 |
Boston
|
|
Combination Drugs Are The Future for Hepatitis C
|
Steve Worland |
11/03/09 |
San Diego
|
|
Dendreon Files Provenge Application to FDA Ahead of Schedule, Now It’s Time to Wait
|
Luke Timmerman |
11/02/09 |
Seattle
|
|
Amylin Strikes $1 Billion Deal with Takeda to Co-Develop Weight Loss Drugs
|
Luke Timmerman |
11/02/09 |
San Diego
|
|
Vertex Hepatitis C Drug Passes Key Test With More Convenient, Twice-Daily Dose
|
Luke Timmerman |
10/31/09 |
Boston
|
|
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs
|
Luke Timmerman |
10/30/09 |
San Diego
|
|
Lilly, With New Focus on Innovation (But Not Necessarily Inclusiveness), Opens San Diego Center for Biotech R&D
|
Bruce V. Bigelow |
10/30/09 |
San Diego
|
|
Idenix Shares Drop as Novartis Walks Away From Hepatitis C Drug
|
Luke Timmerman |
10/30/09 |
Boston
|
|
ZymoGenetics Rival Emerges, Omeros IPO Casts Shadow, Microsoft’s HealthVault Seeks Users, & More Seattle Area Life Sciences News
|
Luke Timmerman |
10/29/09 |
Seattle
|
|
TEDMED Sessions Seek the Patterns in Health Care and Life Sciences That Hold Ideas Together
|
Bruce V. Bigelow |
10/28/09 |
San Diego
|
|
Vertex Hepatitis C Drug Wipes Out Virus For Toughest-to-Treat Patients
|
Luke Timmerman |
10/28/09 |
Boston
|
|
Sequel Pharmaceuticals’ CEO on How to Start a Biotech and Sell it For a Bundle, and Repeat
|
Luke Timmerman |
10/28/09 |
San Diego
|
|
Diabetes drug from San Diego’s Amylin caught up in Aussie Brouhaha
|
Denise Gellene |
10/27/09 |
San Diego
|
|
Arena Positions Weight Loss Drug as the One That Won’t Raise Your Blood Pressure
|
Luke Timmerman |
10/27/09 |
San Diego
|
|
Burnham Recruits Michael Jackson (No Relation) To Create New Drugs
|
Luke Timmerman |
10/26/09 |
San Diego
|
|
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’
|
Luke Timmerman |
10/23/09 |
Boston
|
|
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe
|
Luke Timmerman |
10/21/09 |
Boston
|
|
Isis CEO Vows that Cholesterol Drug, Partnered With Genzyme, Will be “Remarkable” Advance
|
Luke Timmerman |
10/21/09 |
San Diego
|
|
San Diego’s Top 10 Third-Quarter Deals Reveal Slow Comeback in Venture Investing
|
Bruce V. Bigelow |
10/20/09 |
San Diego
|
|
Amgen’s Dmab Faces FDA Delay
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
Calistoga Cancer Drug Shows “Encouraging” Preliminary Results in Small Study
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
Faster, Cheaper Stem Cells: Fate Therapeutics Co-Founder, With Scripps Team, Finds Key
|
Luke Timmerman |
10/18/09 |
National
|
|
Eastbourne Dumps Amylin Shares, Illumina Inks Licensing Deal, Avanir Releases Pseudobulbar Affect Data, & More San Diego Life Sciences News
|
Denise Gellene |
10/15/09 |
San Diego
|
|
Sirtris Advancing No. 1 Drug into Mid-Stage Clinical Trials for Type 2 Diabetes
|
Ryan McBride |
10/14/09 |
Boston
|
|
Alkermes’ Anti-Addiction Drug, Key to Company Pipeline, Passes Early Test
|
Luke Timmerman |
10/13/09 |
Boston
|
|
Dendreon Recruits Genentech CEO, Former Lilly Manufacturing Chief to Board
|
Luke Timmerman |
10/09/09 |
Seattle
|
|
Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent
|
Luke Timmerman |
10/09/09 |
National
|
|
Page 1 of
15 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
